Primary Biliary Cholangitis (PBC) supports investigators studying patient experiences with seladelpar and factors linked to disease progression to better understand patient burden and long-term outcomes.
Funder: Gilead Sciences
Due Dates: November 20, 2026 (Concept submission)
Summary: Supports investigator-initiated research on patient experiences with seladelpar and factors associated with disease progression in primary biliary cholangitis.
Key Information: Comparative analyses of PBC treatments will not be considered; Topic 1 is limited to countries where seladelpar is commercially available.
Gilead Sciences’ Primary Biliary Cholangitis (PBC) Topics of Interest program supports investigator-initiated research addressing gaps in evidence on patient burden and disease progression. Topic 1 seeks real-world research on people with PBC treated with seladelpar, focusing on symptoms and quality of life beyond biochemical measures. Areas of interest include daily functioning, emotional well-being, sleep, disability, work productivity, and relationships between pruritus, quality of life, treatment adherence or persistence, and antipruritic treatment use or refractory pruritus.
Topic 2 focuses on people with alkaline phosphatase (ALP) levels between 1.0 and 1.67 times the upper limit of normal (ULN). It seeks to characterize factors associated with markers of disease progression, better understand long-term outcomes, and connect clinical progression with symptoms and quality of life.